Aktienanalyse zu Xenetic Biosciences Inc (XBIO)XBIOXenetic Biosciences Inc

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenetic Biosciences Inc is not a good buy right now due to significant recent price declines and ongoing losses. The current price is $1.87, which is 62.14% below its 52-week high of $4.94, indicating a weak performance. Additionally, the RSI is at 34.674, suggesting that the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $0.46 million in Q1 2026, which is a continuation of its negative earnings trend, and the forward P/E ratio is currently at 0, indicating no expected earnings growth. The main risk is the recent merger announcement that caused a 48.71% drop in stock price, reflecting market concerns about the future direction of the company.

1 analysts cover XBIO: 1 rate it Buy, 0 Hold and 0 Sell.